Servier To Refresh Neuroscience Space With New RNA-Oriented Precision Medicine Focus
As Immuno-Inflammation Pipeline Advances
The French firm’s stagnant neuroscience franchise will be revamped through a new, strategic focus on RNA-based precision medicines for neurodegenerative diseases including both small- and large-molecule drugs, the company tells Scrip.
